Probi, Viva 5 sign probiotic business deal for North American markets
Both the parties will work together to strenthen the commercial position of Probi brand in the region. Probi CEO Michael Oredsson said the agreement is an important opportunity
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.